- Home
- TRIP vs ZLAB Comparison
TRIP vs ZLAB Comparison
Compare TRIP & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRIP | ZLAB |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.8B |
| IPO Year | 2011 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TRIP | ZLAB |
|---|---|---|
| Price | $9.36 | $18.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $14.88 | ★ $49.44 |
| AVG Volume (30 Days) | ★ 4.1M | 536.1K |
| Earning Date | 05-14-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | 38.46 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $1,556,000,000.00 | $460,156,000.00 |
| Revenue This Year | $3.33 | $14.46 |
| Revenue Next Year | $5.12 | $29.47 |
| P/E Ratio | $31.71 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $9.46 | $15.96 |
| 52 Week High | $20.16 | $44.34 |
Technical Indicators
Market Signals| Indicator | TRIP | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 29.32 | 48.52 |
| Support Level | N/A | $16.77 |
| Resistance Level | $15.37 | $19.70 |
| Average True Range (ATR) | 0.45 | 0.76 |
| MACD | 0.06 | -0.08 |
| Stochastic Oscillator | 4.10 | 55.63 |
Price Performance
Historical ComparisonAbout TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform (33% of 2024 sales). Viator, its experiences brand, was 46% of revenue in 2024, and TheFork, its dining brand, represented 10% of sales (about 8% of revenue were intersegment, which are eliminated from consolidated revenue).
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.